LONG-TERM OUTCOMES OF INTRAVITREAL BEVACIZUMAB THERAPY FOR SUBRETINAL NEOVASCULARIZATION SECONDARY TO IDIOPATHIC MACULAR TELANGIECTASIA TYPE 2

Toygar Okan; Guess Matthew G.; Youssef David S.; Miller Daniel M.

首页> 外文期刊>Retina >LONG-TERM OUTCOMES OF INTRAVITREAL BEVACIZUMAB THERAPY FOR SUBRETINAL NEOVASCULARIZATION SECONDARY TO IDIOPATHIC MACULAR TELANGIECTASIA TYPE 2

【24h】

LONG-TERM OUTCOMES OF INTRAVITREAL BEVACIZUMAB THERAPY FOR SUBRETINAL NEOVASCULARIZATION SECONDARY TO IDIOPATHIC MACULAR TELANGIECTASIA TYPE 2

机译：继发于贝伐他珠单抗治疗继发于2型特发性黄斑部球囊炎的继发于视网膜下神经结膜的长期结果

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose: To assess the long-term visual acuity results for intravitreal bevacizumab therapy in the treatment of subretinal neovascular membrane (SRNVM) secondary to idiopathic macular telangiectasia (Mactel) Type 2.

机译：目的：评估玻璃体内贝伐单抗治疗2型特发性黄斑毛细血管扩张（Mactel）继发的视网膜下新生血管膜（SRNVM）的长期视力结果。

著录项

来源
《Retina》 |2016年第11期|共8页
作者
Toygar Okan; Guess Matthew G.; Youssef David S.; Miller Daniel M.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类眼科学;
关键词
anti-vascular endothelial growth factor; bevacizumab; intravitreal injection; macular telangiectasia; subretinal neovascularization;

机译：抗血管内皮生长因子;贝伐单抗;玻璃体内注射;黄斑毛细血管扩张;视网膜下新生血管;

相似文献

外文文献
中文文献
专利

1. LONG-TERM OUTCOMES OF INTRAVITREAL BEVACIZUMAB THERAPY FOR SUBRETINAL NEOVASCULARIZATION SECONDARY TO IDIOPATHIC MACULAR TELANGIECTASIA TYPE 2 [J] . Toygar Okan, Guess Matthew G., Youssef David S., Retina . 2016,第11期

机译：继发于贝伐他珠单抗治疗继发于2型特发性黄斑部球囊炎的继发于视网膜下神经结膜的长期结果
2. Intravitreal ranibizumab and bevacizumab for bilateral subretinal neovascularization secondary to idiopathic juxtafoveal telangiectasia type 2A [J] . Nikolaos Mavrakanas, Efstratios Mend-rinos, Constantin J. Pournaras Joel Salzmann Acta ophthalmologica Scandinavica . 2009,第8期

机译：玻璃体腔内兰尼单抗和贝伐单抗用于继发于2A特发性近中眼凹毛细血管扩张的双侧视网膜下新生血管形成
3. Intravitreal bevacizumab (Avastin) for subretinal neovascularization secondary to type 2A idiopathic juxtafoveal telangiectasia [J] . Subrata Mandal, Pradeep Venkatesh, Zahir Abbas, Graefe's Archive for Clinical and Experimental Ophthalmology . 2007,第12期

机译：玻璃体内贝伐单抗（Avastin）用于继发于2A型特发性近中眼凹毛细血管扩张的视网膜下新生血管形成
4. Photodynamic Therapy for Treatment Subretinal Neovascularization [C] . Sergey E. Avetisov, Maria V. Budzinskaja, Tatyana N Kiseleva, Conference on Therapeutic Laser Applications and Laser-Tissue Interactions III . 2007

机译：光动力疗法治疗视网膜下新生血管
5. Clinical Features of Treated and Untreated Type 1 Idiopathic Macular Telangiectasia Without the Occurrence of Secondary Choroidal Neovascularization Followed for 2 Years in Japanese Patients [D] . 逢坂理恵 2019

机译：在日本患者中治疗和未治疗的1型特发性黄斑部毛细血管扩张症的临床特征为继发性脉络膜新血管形成，随访2年
6. Predictors of visual outcome in eyes with choroidal neovascularization secondary to age related macular degeneration treated with intravitreal bevacizumab monotherapy [O] . Jay Chhablani, Jae Suk Kim, William R Freeman, 2013

机译：玻璃体腔注射贝伐单抗单药治疗年龄相关性黄斑变性继发脉络膜新生血管的眼睛的视觉预后
7. Combined photodynamic therapy and intravitreal bevacizumab as primary treatment for subretinal neovascularization associated with type 2 idiopathic macular telangiectasia [O] . Rishi, Pukhraj, Rishi, Ekta, Shroff, Daraius 2009

机译：结合光动力疗法和玻璃体内贝伐单抗作为与2型特发性黄斑毛细血管扩张相关的视网膜下新生血管的主要治疗方法

LONG-TERM OUTCOMES OF INTRAVITREAL BEVACIZUMAB THERAPY FOR SUBRETINAL NEOVASCULARIZATION SECONDARY TO IDIOPATHIC MACULAR TELANGIECTASIA TYPE 2

摘要

著录项

相似文献

相关主题

期刊订阅